Flindr Therapeutics

Private

OssHealthcare & Life Scienceshttps://flindrtx.com/

Last Round

Series A

Apr 24, 2024

Total Funding Raised

$21.4M

Company Overview

Flindr Therapeutics is a biotechnology company developing a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small molecule inhibitorsprecision oncologyfirst-in-class therapiesRNF31 inhibitortarget discoverydrug discovery enginepre-clinical biotechE3 ubiquitin ligasedrug licensingreverse translationHOIP inhibitorB-cell lymphoma treatmentovarian cancer treatmentAI-enabled drug discoveryIND applicationstructure-based drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flindr Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Flindr Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Flindr Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Apr 24, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

Maarten Ligtenberg

Chief Executive Officer At Flindr Therapeutics

Executive Team

Flindr Therapeutics Investors

Notable investors and investment history

Flindr Therapeutics investors
Investor	Rounds
Brabantse Ontwikkelings Maatschappij	Seed, Series A
Swanbridge Capital	Seed, Series A
Innovatiefonds Noord-Holland	Seed
V-Bio Ventures	Series A
Oncode Institute	Seed, Series A
PMV	Series A
Johnson & Johnson Innovation - JJDC, Inc.	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 24, 2026
Monthly visitors increased 505% MoM, from 74 to 448.
May 12, 2025
Grew 40% QoQ from 10 to 14 employees.

View all signals

Flindr Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Flindr Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Flindr Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOss

Employee Range19

Year Founded2020

Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.